Biosimilars, also known as follow-on-biologics are “duplicate” and licensed versions of the biologics that have lost their patent and are
More
Biosimilars, also known as follow-on-biologics are “duplicate” and licensed versions of the biologics that have lost their patent and are
More
The Korean pharma market is experiencing significant growth in finished drug products, according to CPhI Korea. Over the last 12
More
The global pharma market was worth $934.8 billion in 2017 and will reach $1170 billion in 2021, growing at 5.8%,
More